ArticleBMC nutrition2026
Efficacy of the nano curcumin supplementation on fibrosis, steatosis, inflammatory and metabolic status of liver fibrosis patients with non-alcoholic fatty liver origin: a study protocol for a double-blind randomized controlled trial.
Article in BMC nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver disease related to alcohol consumption and non-alcoholic fatty liver disease (NAFLD) are among the leading causes of liver fibrosis. Curcumin, due to its anti-fibrotic and anti-inflammatory effects, has been proposed as a potential therapeutic agent. However, its clinical application is limited by poor stability, solubility, and bioavailability. Nanocurcumin, a nano-formulated version of curcumin, overcomes these limitations. This study aims to evaluate the efficacy of Nanocurcumin supplementation in improving fibrosis, steatosis, inflammation, and metabolic status in patients with liver fibrosis of NAFLD origin.
methodsThis double-blind, randomized, placebo-controlled trial is being conducted at the Gastroenterology Clinic of Shariati Hospital (Tehran, Iran). Fifty patients aged 30 to 70 years are enrolled and randomly assigned to the intervention or placebo group using a block balanced randomization method. The intervention group receives one capsule of Nanocurcumin (40 mg, twice daily), while the placebo group receives an identical placebo capsule. The primary outcomes include liver fibrosis and steatosis, assessed via FibroScan at baseline and at the end of the study. Secondary outcomes include changes in inflammatory markers, metabolic parameters, liver function tests, anthropometric measures, and blood pressure over the 16-week intervention period. DISCUSSION: This trial is currently ongoing. Recruitment is expected to be completed by the end of 2024, and the trial is anticipated to be fully completed by mid-2025. If Nanocurcumin supplementation demonstrates positive efficacy, it may serve as a potential therapeutic approach for patients with liver fibrosis.
trial registrationIranian Registry of Clinical Trials IRCT20210427051098N2 (Available from: https://irct.behdasht.gov.ir). Date and version identifier: April 20, 2023; approved version by the IRCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.